Soligenix (NASDAQ:SNGX) Announces Quarterly Earnings Results, Beats Expectations By $0.43 EPS

Soligenix (NASDAQ:SNGX) announced its quarterly earnings data on Tuesday. The biopharmaceutical company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.43, FiscalAI reports.

Soligenix Stock Up 6.3%

Shares of Soligenix stock traded up $0.07 on Tuesday, hitting $1.18. 201,944 shares of the company traded hands, compared to its average volume of 336,732. Soligenix has a 12-month low of $1.00 and a 12-month high of $6.23. The company has a market cap of $11.91 million, a PE ratio of -0.33 and a beta of 1.99. The company has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.42.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Soligenix presently has a consensus rating of “Hold” and an average target price of $6.00.

Institutional Trading of Soligenix

A number of institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Soligenix during the fourth quarter worth approximately $37,000. StoneX Group Inc. acquired a new position in Soligenix during the fourth quarter valued at approximately $50,000. Jane Street Group LLC bought a new position in shares of Soligenix in the fourth quarter valued at approximately $51,000. Banco BTG Pactual S.A. acquired a new stake in shares of Soligenix in the third quarter worth $54,000. Finally, Virtu Financial LLC acquired a new stake in shares of Soligenix in the third quarter worth $59,000. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.